A new human carcinoma cell line, UMK-1, was established from primary urinary bladder carcinoma with histological diagnosis of transitional cell carcinoma grade 2, with squamous and adenocarcinomatous differentiation. These histologic features were maintained in the cultured cells and in xenografted tumors in nude mice. Ultrastructurally, the cultured cells were characterized by formation of glandular structure with well-formed junctional complexes and microvilli, intracytoplasmic lumina and tonofilament bundles. Upon continuous propagation in serum-free medium, UMK-1 cells secreted gelatinases and tissue inhibitor of metalloproteinase (TIMP)-1 into the conditioned medium. The gelatinolytic activities which were inhibited by EDTA, were composed of a major band at 95 kD and a minor band at 68 kD on gelatin zymography. The measurement of TIMP-1 in the conditioned medium was performed by the one-step sandwich enzyme immunoassay system. The production of gelatinases and TIMP-1 was observed during the late log phase of the cell growth and those productions showed similar kinetics. UMK-1 cells can be used to study the interaction of tumor cell-derived gelatinolytic protein-ases and TIMP-1 in cancer invasion and metastasis.

Keywords:
Human bladder cancer cell line, Mixed carcinoma, Gelatinase, TIMP-1
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.